Latest Puramed Bioscience (PMBS) Headlines En
Post# of 73
Posted On: 03/11/2014 12:36:35 AM
Latest Puramed Bioscience (PMBS) Headlines
Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.
Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
PR Newswire - Fri Nov 29, 8:00AM CST
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.
PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.
PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.
PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BBMBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..
PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.
LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.
PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BBMBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.
PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.
PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.
PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
PR Newswire - Thu May 30, 10:11AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.
PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
PR Newswire - Thu May 23, 1:10PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.
LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
PR Newswire - Tue May 21, 1:33PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic® M, has "robust efficacy".
PuraMed BioScience®, Inc., Launches Its Business-to-Business Migraine First Aid Kit(TM) to Promote Workplace Health and Wellness
PR Newswire - Wed May 15, 3:01PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit(TM). The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms.
PuraMed BioScience reaches agreement with Biokemical for distribution of LipiGesic M in Colombia, South America
M2 - Tue May 14, 8:34AM CDT
Healthcare products company PuraMed BioScience Inc (PMBS:OTCBB) reported on Monday that it has received its first International order for its non-drowsy, clinically tested, over-the-counter migraine relief product, LipiGesic M.
PuraMed BioScience® Expands International Distribution with Order from Colombia, South America
PR Newswire - Mon May 13, 10:13AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces the receipt of its first International order for LipiGesic® M its non-drowsy, clinically tested, over-the-counter migraine relief product.
Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
PR Newswire - Wed Apr 24, 8:49AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic® M. Report Highlights
PuraMed BioScience to Expand Marketing of Over-the-Counter Migraine Product to Additional National Retail Chains
PR Newswire - Fri Apr 12, 11:34AM CDT
Healthcare product developer PuraMed BioScience®, Inc. (PMBS: OTCBB) announced plans this week to expand the retail sales efforts of its OTC migraine product LipiGesic® M to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. PuraMed has selected its targeted retailers according to various material criteria, including cost of entry, geography, demographics and consumer preference.
Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.
Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
PR Newswire - Fri Nov 29, 8:00AM CST
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants. PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB
MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com.. PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com. LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache. PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB
MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013. PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.
PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication. PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
PR Newswire - Thu May 30, 10:11AM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
PR Newswire - Thu May 23, 1:10PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.
LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
PR Newswire - Tue May 21, 1:33PM CDT
PuraMed BioScience®, Inc., (OTCBB
MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic® M, has "robust efficacy". PuraMed BioScience®, Inc., Launches Its Business-to-Business Migraine First Aid Kit(TM) to Promote Workplace Health and Wellness
PR Newswire - Wed May 15, 3:01PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit(TM). The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms.
PuraMed BioScience reaches agreement with Biokemical for distribution of LipiGesic M in Colombia, South America
M2 - Tue May 14, 8:34AM CDT
Healthcare products company PuraMed BioScience Inc (PMBS:OTCBB) reported on Monday that it has received its first International order for its non-drowsy, clinically tested, over-the-counter migraine relief product, LipiGesic M.
PuraMed BioScience® Expands International Distribution with Order from Colombia, South America
PR Newswire - Mon May 13, 10:13AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces the receipt of its first International order for LipiGesic® M its non-drowsy, clinically tested, over-the-counter migraine relief product.
Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
PR Newswire - Wed Apr 24, 8:49AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic® M. Report Highlights
PuraMed BioScience to Expand Marketing of Over-the-Counter Migraine Product to Additional National Retail Chains
PR Newswire - Fri Apr 12, 11:34AM CDT
Healthcare product developer PuraMed BioScience®, Inc. (PMBS: OTCBB) announced plans this week to expand the retail sales efforts of its OTC migraine product LipiGesic® M to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. PuraMed has selected its targeted retailers according to various material criteria, including cost of entry, geography, demographics and consumer preference.
(0)
(0)